色又黄又爽18禁免费网站现观看,无码人妻一区二区三区兔费,国产精品久久国产精无码懂色,欧美日韩国产二区

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
產(chǎn)品中心-北京博奧森生物技術(shù)有限公司
Human Fibrinogen (from plasma) (bs-1240P)  
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@bioss.com.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
說(shuō)明書(shū): 10mg  100mg  250mg
10mg/240.00元
100mg/1200.00元
250mg/2400.00元
大包裝/詢價(jià)

產(chǎn)品編號(hào) bs-1240P
英文名稱 Human Fibrinogen (from plasma)
中文名稱 人纖維蛋白原(進(jìn)口)
別    名 Factor I; FGA; FGA protein; FGB; FGG; Fib2; Fibrinogen A alpha polypeptide; Fibrinogen A alpha polypeptide chain; Fibrinogen alpha chain; Fibrinogen B alpha polypeptide; Fibrinogen beta chain; Fibrinogen G alpha polypeptide; Fibrinogen gamma chain; MGC104327; MGC119422; MGC119423; MGC119425; MGC120405; FIBRINOGEN, HUMAN TYPE I FROM HUMAN PLAS; Fibrinogen from human plasma (Native)  纖維蛋白原 來(lái)源于人類血漿;
Specific References  (1)     |     bs-1240P has been referenced in 1 publications.
[IF=3.55] Huang, Mo, et al. "Solidified liquid layer model makes quartz crystal microbalance a convenient molecular ruler." Colloids and Surfaces B: Biointerfaces 85.1 (2011): 92-96.  Other ;  
性    狀 Lyophilized
物    種 Human
序    列 Purified native protein
純    度 50-70% protein basis (biuret)
內(nèi)毒素 Not analyzed
活性 Yes
保存條件 Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Fibrinogen is the main protein of blood coagulation system. It is a large protein and it consists of two identical subunits that contain three polypeptide chains: alpha, beta and gamma. All chains are connected with each other by a number of disulfide bonds. Fibrinopeptides A (1 to 16 amino acids) and B (1 to 17 amino acids) are released by thrombin from the N terminal parts of alpha and beta chains, respectively. In this way fibrinogen is converted into fibrin, which by means of polymerization forms a fibrin clot. Fibrinogen clotting underlies pathogenesis of MI, thromboembolism and thromboses of arteries and veins, since fibrin is the main substrate for thrombus formation. Fibrinogen activation is also involved in pathogenesis of inflammation, tumor growth and many other diseases. The normal fibrinogen concentration in plasma is about 3 mg/ml. The elevated level of fibrinogen in patient's blood is regarded as an independent risk factor for cardiovascular diseases. An increase in blood fibrinogen concentration was shown to be a strong predictor of coronary heart disease (Sonel A. et al, and Rapold H.J. et al). All these facts make fibrinogen an important parameter in the diagnosis of cardiovascular diseases.


SWISS:
P02671

Gene ID:
2243

基本信息:

CAS:9001-32-5

MDL:MFCD00131060
分子量:α-chain 63.5 kDa; β-chain 56 kDa;γ chain 47 kDa; soluble dimer 340 kDa; 
來(lái)源:human plasma(源材料均已通過(guò)HIV和HBsAg的陰性測(cè)試。
蛋白質(zhì)量:50-70% protein basis (biuret)(≥80%蛋白質(zhì)可凝固)

性狀:凍干粉(含~15%的檸檬酸鈉和~25%的氯化鈉

溶解性:0.9% NaCl: soluble 10 mg/mL

產(chǎn)品簡(jiǎn)介:

纖維蛋白原(Fibrinogen),或因子I,是一種血液蛋白,參與凝血并被凝血酶轉(zhuǎn)化為纖維蛋白。纖維蛋白原的分子量約為340kDa。

生化/生理作用:

纖維蛋白原(Fibrinogen)是一種急性期蛋白,是蛋白質(zhì)凝血級(jí)聯(lián)反應(yīng)的一部分。級(jí)聯(lián)反應(yīng)的最終結(jié)果是產(chǎn)生了將纖維蛋白原轉(zhuǎn)化為纖維蛋白的凝血酶。凝血酶蛋白迅速水解纖維蛋白原,釋放纖維蛋白肽A。這種小肽的丟失不足以使產(chǎn)生的纖維蛋白分子不溶解,但它傾向于與相鄰的纖維蛋白和纖維蛋白原分子形成復(fù)合物。 然后凝血酶從纖維蛋白中裂解出第二種肽纖維蛋白肽B,然后形成的纖維蛋白單體自發(fā)聚合形成不溶性凝膠。聚合的纖維蛋白通過(guò)非共價(jià)鍵和靜電力保持在一起,并被轉(zhuǎn)酰胺酶,XIIIa因子穩(wěn)定,XIIIa因子是凝血酶作用于XIII因子而產(chǎn)生的。然后不溶性纖維蛋白聚集體(凝塊)和聚集的血小板阻塞受損的血管并防止進(jìn)一步出血。血漿中纖維蛋白原的量可作為體內(nèi)是否存在炎癥過(guò)程的非特異性指標(biāo)。來(lái)自任何哺乳動(dòng)物來(lái)源的纖維蛋白原將被來(lái)自任何哺乳動(dòng)物來(lái)源的凝血酶切割。

重構(gòu):

溶解纖維蛋白原的最佳方式就是將之置于溫?zé)岬?37oC)生理鹽水上,因?yàn)槔w維蛋白原不溶于水。 生理鹽水的濃度可在0.85至0.9%范圍內(nèi)。 纖維蛋白原鹽水溶液可以輕輕攪拌,但不能漩渦。 纖維蛋白原會(huì)慢慢溶解,形成一種霧狀的溶液。 纖維蛋白原可經(jīng)過(guò)過(guò)濾滅菌,但不能采用0.1μ的過(guò)濾器。 纖維蛋白原會(huì)慢慢溶解,形成一種霧狀的溶液。 不可采用真空過(guò)濾,因?yàn)檫^(guò)濾過(guò)程將導(dǎo)致分子的破壞。


產(chǎn)品圖片
The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.
版權(quán)所有 2004-2026 www.bklrv.cn 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)